BRPI0412803A - alfa-fetoproteìna humana não-glicosilada, métodos de produção e usos dos mesmos - Google Patents

alfa-fetoproteìna humana não-glicosilada, métodos de produção e usos dos mesmos

Info

Publication number
BRPI0412803A
BRPI0412803A BRPI0412803-6A BRPI0412803A BRPI0412803A BR PI0412803 A BRPI0412803 A BR PI0412803A BR PI0412803 A BRPI0412803 A BR PI0412803A BR PI0412803 A BRPI0412803 A BR PI0412803A
Authority
BR
Brazil
Prior art keywords
fetoprotein
production methods
human alpha
unglycosylated human
unglycosylated
Prior art date
Application number
BRPI0412803-6A
Other languages
English (en)
Inventor
Robert Mulroy
Ian Krane
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of BRPI0412803A publication Critical patent/BRPI0412803A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)

Abstract

"ALFA-FETOPROTEìNA HUMANA NãO-GLICOSILADA, MéTODOS DE PRODUçãO E USOS DOS MESMOS". A presente invenção refere-se a alfa-fetoproteína humana nãoglicosilada, métodos de produção e usos dos mesmos.
BRPI0412803-6A 2003-07-22 2004-07-21 alfa-fetoproteìna humana não-glicosilada, métodos de produção e usos dos mesmos BRPI0412803A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/624,380 US7208576B2 (en) 1999-01-06 2003-07-22 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
PCT/US2004/023474 WO2005010165A2 (en) 2003-07-22 2004-07-21 Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0412803A true BRPI0412803A (pt) 2006-09-26

Family

ID=34103214

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412803-6A BRPI0412803A (pt) 2003-07-22 2004-07-21 alfa-fetoproteìna humana não-glicosilada, métodos de produção e usos dos mesmos

Country Status (10)

Country Link
US (2) US7208576B2 (pt)
EP (1) EP1648918A4 (pt)
JP (1) JP2006527998A (pt)
KR (1) KR20060052865A (pt)
CN (1) CN100497369C (pt)
AU (1) AU2004260129A1 (pt)
BR (1) BRPI0412803A (pt)
CA (1) CA2526814A1 (pt)
IL (1) IL172880A (pt)
WO (1) WO2005010165A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015709A1 (en) * 1999-09-02 2001-03-08 Atlantic Biopharmaceuticals, Inc. USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS
JP2010513518A (ja) * 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
EP2124996A4 (en) * 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
WO2009124056A2 (en) * 2008-04-01 2009-10-08 Merrimack Pharmaceuticals, Inc. Alpha-fetoprotein for treating disease
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
CN102993292A (zh) * 2012-12-14 2013-03-27 上海柯莱逊生物技术有限公司 一种afp重组蛋白和体外重组表达的方法
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
CN104371017B (zh) * 2014-07-04 2018-03-16 嘉兴博泰生物科技发展有限公司 一种高效表达与制备外分泌型人源afp的方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN117916253A (zh) * 2021-07-23 2024-04-19 阿尔法癌症技术公司 用于疾病治疗的甲胎蛋白生物缀合物
CN116769912B (zh) * 2023-06-09 2024-03-19 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用于检测肝癌AFP mRNA的试剂盒

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
US4692332A (en) 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US4970071A (en) 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4966753A (en) 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
JPH025866A (ja) 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
JP2686819B2 (ja) 1989-05-01 1997-12-08 雪印乳業株式会社 α―フェトプロテイン遺伝子のエンハンサーに結合する蛋白質をコードするＤＮＡ
WO1991005041A1 (en) 1989-09-26 1991-04-18 Townes Tim M Erythroid-specific gene expression system
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5206153A (en) 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
JPH0673457B2 (ja) 1990-11-07 1994-09-21 雪印乳業株式会社 α―フェトプロティン遺伝子のエンハンサーに結合する蛋白質をコードするＤＮＡ
AU1228592A (en) 1991-01-11 1992-08-17 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
JPH06509474A (ja) 1991-07-31 1994-10-27 ローヌ−プーラン・ローラー・インターナシヨナル（ホールデイングス）インコーポレイテツド 蛋白質のトランスジェニック生産
WO1993005774A1 (en) 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
US6331611B1 (en) 1991-09-27 2001-12-18 Mcgill University Expression and purification of cloned human alpha-fetoprotein
CA2120131A1 (en) 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
DK75393D0 (da) 1993-06-24 1993-06-24 Symbicom Ab Production of protein
US5804407A (en) 1993-11-04 1998-09-08 University Technologies International, Inc. Method of expressing genes in mammalian cells
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene
DK0755446T3 (da) 1994-04-25 2007-01-29 Genentech Inc Cardiotrophin og anvendelser deraf
US5880327A (en) 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
JPH10513347A (ja) 1995-01-24 1998-12-22 ロバート エイ． マルギタ 組換え型ヒトα−フェトプロテインおよびその利用
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5965428A (en) * 1996-10-08 1999-10-12 Ecogen, Inc. Chimeric lepidopteran-toxic crystal proteins
US7098306B2 (en) * 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
EP1148779B1 (en) 1999-01-06 2007-12-12 Merrimack Pharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
EP1161533A1 (en) * 1999-03-09 2001-12-12 Atlantic Biopharmaceuticals, Inc. Expression of human alpha-fetoprotein in mammalian cells
WO2001015709A1 (en) 1999-09-02 2001-03-08 Atlantic Biopharmaceuticals, Inc. USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS

Also Published As

Publication number Publication date
CN1826350A (zh) 2006-08-30
IL172880A0 (en) 2006-06-11
US20070169211A1 (en) 2007-07-19
JP2006527998A (ja) 2006-12-14
AU2004260129A1 (en) 2005-02-03
US20040098755A1 (en) 2004-05-20
CN100497369C (zh) 2009-06-10
US7208576B2 (en) 2007-04-24
IL172880A (en) 2010-11-30
KR20060052865A (ko) 2006-05-19
CA2526814A1 (en) 2005-02-03
EP1648918A2 (en) 2006-04-26
WO2005010165A2 (en) 2005-02-03
WO2005010165A3 (en) 2005-04-28
EP1648918A4 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
LTC1425001I2 (lt) Fenetanolamino dariniai, skirti kvėpavimo ligoms gydyti
ES1054821Y (es) Peonza de juguete
DE60209785D1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
BRPI0412803A (pt) alfa-fetoproteìna humana não-glicosilada, métodos de produção e usos dos mesmos
DK1553840T3 (da) Indkapslede funktionelle bageri-ingredienser
DE60221143D1 (de) Brusteinlage enthaltend hautpflegemittel
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
BR0212250B1 (pt) produto de cuidado pessoal.
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
PT1500654E (pt) Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
BR0306905A (pt) Vacinas de flavivìrus
DE60207646D1 (de) Visierscheibe
EP1809661A4 (en) HUMAN INTERFERON-BETA-MUTEIN
DE60223576D1 (de) Hautbehandlungszusammensetzung
NL1024677A1 (nl) Therapeutische prolinederivaten.
DE50203644D1 (de) Abseilvorrichtung
ES1051506Y (es) Juguete de composicion.
BRPI0410638A (pt) derivados de azitromicina
DE60302964D1 (de) Verbesserte Augenlidpositionierung
FR2852042B1 (fr) Piece d'aretier
FR2822930B1 (fr) Bougie decorative
MA25706A1 (fr) Fauteuil de coiffeur
ITMI20031273A1 (it) Composizioni a base di cenere di vegetali per la terapia di affezioni cutanee.
ITMI20021442A1 (it) Protezione cutanea mediante fenilbutenoidi

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: MERRIMACK PHARMACEUTICALS, INC (US)

B25G Requested change of headquarter approved

Owner name: MERRIMACK PHARMACEUTICALS, INC (US)

B25A Requested transfer of rights approved

Owner name: ALPHA CANCER TECHNOLOGIES INC. (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL